Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes

Area of Science:

• Biochemistry
• Cell Biology
• Endocrinology

Background:

• Diabetic dyslipidemia causes cellular dysfunction by altering plasma membrane cholesterol levels.
• Liver X receptors (LXRs) are key regulators of cellular cholesterol and inflammation.
• Selective LXR agonists like DMHCA offer a potential therapeutic strategy.

Purpose of the Study:

• To investigate the effects of DMHCA on diabetic cellular dysfunction.
• To elucidate the molecular mechanisms of DMHCA in type 2 diabetic mice and human circulating angiogenic cells (CACs).

Main Methods:

• Multisystem approach in type 2 diabetic (db/db) mice and human CACs.
• Single-cell RNA sequencing of hematopoietic stem cells (HSCs).

Main Results:

• DMHCA corrected retinal and bone marrow (BM) dysfunction, restoring cholesterol homeostasis and membrane fluidity.
• DMHCA reduced systemic inflammation and corrected BM pathology.
• DMHCA treatment modulated HSCs, decreasing myeloidosis and increasing CACs and erythrocyte progenitors.

Conclusions:

• DMHCA effectively ameliorates diabetes-induced retinal and BM pathology.
• DMHCA demonstrates therapeutic potential for diabetic complications by targeting LXR pathways.